Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: Results from five randomized controlled trials by Vernon, C.C. (Clare) et al.
Int. J. Radiation Oncology Biol. Phys., Vol. 35, No. 4, pp. 73 l-744, 1996 
Copyright 0 1996 Elsevier Science Inc. 
hinted in the USA. All tights reserved 
036Q-3016/96 $15.00 + 00 
ELSEVIER PII: SO360-3016(%)00154-X 
l Hypertherrnia Original Contribution 
RADIOTHERAPY WITH OR WITHOUT HYPERTHERMIA IN THE 
TREATMENT OF SUPERFICIAL LOCALIZED BREAST CANCER: 
RESULTS FROM FIVE RANDOMIZED CONTROLLED TRIALS 
INTERNATIONAL COLLABORATIVE HYPERTHERMIA GROUP: 
UK Medical Research Council: CLARE C. VERNON, M.A., F.R.C.R.,* 
JEFFREY W. HAND, PH.D., D.Sc.,* STANLEY B. FIELD, PH.D.,* 
DAV~DMACHIN, M.Sc., PH.D.+ AND JILLB. WHALEY, B.V.M.&St 
European Society for Hyperthermic Oncology and the Dutch Hyperthermia Group: 
JACOBA VAN DER ZEE, M.D., PH.D.,* WIM L. J. VAN PUT-TEN, M.Sc.,* 
GERARD C. VAN RHOON, PH.D.,$ JAN D. P. VAN DIJK, PH.D.” AND 
DIONISIO GONZALEZ GONZALEZ, M.D., PH.D.§ 
Princess Margaret HospitaVOntario Cancer Institute: FEI-FEI LIU, M.D., F.R.C.P.C.,j’ 
PHYLLIS GOODMAN, M.Sc! AND MICHAEL SHERAR, F%.D! 
*MRC Cyclotron Unit, Hammersmith Hospital, London, United Kingdom; +MRC Cancer Trials Office, Cambridge, 
United Kingdom; *Departments of Hyperthermia and Statistics, Daniel den Hoed Cancer Center, Rotterdam,The 
Netherlands; “Department of Radiotherapy, Academic Medical Center, Amsterdam,The Netherlands; apartments of 
Radiation Oncology, Biostatistics, and Clinical Physics, Princess Margaret Hospital/Ontario Cancer Institute, 
University of Toronto, Canada 
purpose: Claims for the value of hyperthermia as an adjunct to radiotherapy in the treatment of cancer have 
mostly been based on small Phase I or II trials. To test the benefit of thii form of treatment, randomized phase 
III trials were needed. 
Methods and Materials: Five randomized trials addressing this question were started between 1988 and 1991. In 
these trials, patients were eligible if they had advanced prhnary or recurrent breast cancer, and local radiotherapy 
was indicated in preference to surgery. In addition, heating of the lesions and treatment with a prescribed 
(re)irradiation schedule had to be feasible and informed consent was obtained. The primary endpoint of ail trials 
was local complete response. Slow recruitment led to a decision to collaborate and combii the trial rest&s in 
one analysis, and report them simuhaneously in one publication. Interim analyses were carried out and the trials 
were closed to recruitment when a previously agreed statistically sign&ant difference in complete response rate 
was observed in the two larger trials. 
Results: We report on pretreatment characteristics, the treatments received, the local response observed, duration 
of response, time to local failure, distant progression and survival, and treatment toxicity of tbe 306 patients 
randomized. The overali CR rate for RT alone was 41% and for the combined treatment arm was 59%, giving, 
after stratification by trial, an odds ratio of 2.3. Not alI trials demonstrated an advantage for the combined 
treatment, although tbe 95% confidence intervals of the different trials all contain the pooled odds ratio. The 
greatest effect was observed in patients with recurrent lesions in previously irradiated areas, where further 
irradiation was limited to low doses. 
Conclusion: The combined result of the five trials has demonstrated the efficacy of hyperthemia as an adjunct 
to radiotherapy for treatment of recurrent breast cancer. The implication of these encouraging results is that 
hyperthermia appears to have an important role in the clinical management of this disease, and there should be 
no doubt that further studies of the use of hypertbermia are warranted. 
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INTRODUCTION 
Early clinical applications of hyperthermia (HT) include 
those of Coley (5) and Westermark (34) whereas the or- 
igins of the use of HT as a radiosensitizing agent are to 
be found in the early years of the present century (20,26). 
Although there was periodic interest through the interven- 
ing years, progress in the clinical application of HT was 
largely frustrated by a lack of adequate techniques for 
heating tumors. Development of a biological rationale for 
the use of heat began during the 1960s and, in recent years, 
the considerable effort applied to the physics and engi- 
neering problems associated with clinical HT has led to 
the development of acceptable techniques for treatment of 
superficial tumors (10). Sufficient knowledge has also 
been gained about methods of applying HT, with respect 
to fractionation and combination with other modalities, to 
result in a safe and possibly effective clinical treatment. 
As a consequence, a large number of clinical Phase I 
and II studies (11, 15, 24, 27, 32, 33) have been carried 
out and their results indicate that HT may be of value in 
cancer treatment when given as an adjunct to either radio- 
therapy (RT) or chemotherapy. A few randomized clinical 
trials have also been performed (9,25,31) but, in most of 
these, the numbers of patients recruited were too small or 
the lesions were not properly heated. It became clear that 
properly conducted prospectively randomized trials were 
needed to define the role of HT in cancer management. A 
trial in patients with malignant melanoma reported by Ov- 
ergaard et al. in 1995 (21) was undertaken for the same 
reasons. 
For patients with breast cancer, previous studies have 
indicated that local treatment does not affect survival in 
patients with recurrent disease, and that distant metastases 
will be detected ultimately in 75-93% of patients (1, 4, 
28). The median survival time for these patients ranges 
from 12-53 months, depending on tumor characteristics, 
and 21-50% will survive 5 years or longer (4). Local 
recurrence causes pain, bleeding, and ulceration in over 
60% of patients (3), in addition to the psychological dis- 
tress of watching a tumor grow. For both nonirradiated 
and previously irradiated recurrences, durable local con- 
trol decreases with increasing size of the lesion and, for 
the latter group of patients, the radiation dose that can be 
administered safely is lower than that considered effective. 
Chemotherapy is also less effective in areas that have pre- 
viously been irradiated. Thus, the use of a local treatment 
that can provide durable local tumor control for the re- 
maining lifespan of these patients would be considered 
worthwhile. 
The optimum HT regimen with regard to temperature 
or number of treatments is not known. However, a small 
number of I-IT fractions may be as effective as a larger 
number because of the development of thermotolerance 
(14). The need to select appropriate patients and tumors 
and the importance of compliance with appropriate quality 
assurance guidelines when delivering HT treatment has 
been highlighted by the results of previous clinical trials, 
especially Perez et aZ. (25). 
The key question addressed by the randomized trials 
reported here was whether or not the addition of HT treat- 
ment to RT increased the complete response (CR) rate in 
patients suffering from recurrent or inoperable primary 
breast cancer. 
METHODS AND MATERIALS 
Trial design 
The five randomized trials, with individual patient data 
combined in this analysis, were each planned indepen- 
dently with their own design, sample size requirements 
and, in some cases, stopping rules. All trials examined the 
effect of the addition of HT treatment to RT for treatment 
of breast cancer and the primary endpoint of each of the 
five trials was the local tumor response. The trials were 
performed by four collaborating groups: the Dutch Hy- 
perthermia Group at the Academic Medical Center in Am- 
sterdam and the Daniel den Hoed Cancer Center in Rot- 
terdam (trial DHG), the Medical Research Council (MRC) 
hyperthermia group at the Hammersmith Hospital, Lon- 
don, UK, (trials MRC BrI and MRC BrR), the European 
Society of Hyperthermic Oncology (ESHG), (trial 
ESHO), and the hyperthermia group at the Princess Mar- 
garet Hospital/Ontario Cancer Institute, Toronto, Canada 
(trial PMH). The groups in Rotterdam and London coor- 
dinated multicenter trials. 
At the design stage of each trial, sample sizes were cal- 
culated on the basis of the anticipated CR rate to RT alone 
and the anticipated increased response rates, S, for RT + 
HT together with test size (Y = 0.05 and power 1-p = 0.8 
(18). The basis of these calculations is summarised for the 
individual trials in Table 1 together with the correspond- 
ing recruitment targets. 
The decision to combine the information from the 
ESHO and two MRC trials was made in October 1990, 
because it had become clear that the accrual rate of the 
separate trials was too low to reach their individual design 
targets. In particular, without the prospect of combining 
the results, the MRC trials would have been closed to re- 
cruitment, leaving, at best, considerable uncertainty about 
the real effect of HT. Given the similarities in design of 
the ESHO and MRC trials, it was possible to plan to com- 
bine prospectively the analysis of these three trials without 
altering the design or data management procedures of the 
individual trials. The MRC trials had included a third 
group, within the same protocol, of patients with head and 
neck nodes, which recruited only 9 patients and which was 
closed at the time of the decision to combine with the 
ESHO group. These patients are not included in this re- 
port. Just prior to this stage, following an interim analysis 
and a review of more recent literature, the required num- 
ber of patients was recalculated for the MRC trials, as- 
suming a two-tailed test size and power, but an odds ratio 
(OR) for obtaining a local CR equal to 2, corresponding 
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Table 1. Anticipated complete response (CR) rates to radiotherapy (RT), anticipated benefit by the addition of hyperthermia (HT), 
planned trial size, date of opening, and final patient accrual 
Trial 
Anticipated CR % 
RT RT + HT 
Anticipated 
benefit S 
(%) 
odds Total Date trial 
ratio planned opened 
Final accrual 
RT RT + HT 
DHG 30 60 30* 3.5 80 May ‘88 19 19 
MRC BrI 
MRC BrR I 
45 55 lo+ 1.5 800’ Jan ‘89 71 108 
ESHO 20-60 40-80 20* 2.25 152 Ott ‘89 29 27 
PMH 35-50 55-75 20+ 2.5 234 July ‘91 16 17 
Total 
* One-sided a = 0.05. 
+ Two-sided (Y = 0.05. 
1266 135 171 
t Originally planned sample size 800 for all MRC trials combined, with a 60:40 randomization in favor of the HT arm. 
Recalculation in September 1990 following an interim analysis based on the first 67 patients, assuming a larger treatment effect (6 
= 17%), led to a reduced target recruitment of 280. 
to a difference in CR rates of S = 17%. This gave a revised 
target recruitment of 280 patients. After including the 
ESHO trial, this target was retained for the combined anal- 
ysis. Subsequently, the opportunity arose to include the 
DHG and PMH trials within the collaboration in 1992, 
retaining the combined recruitment target of 280. For pur- 
poses of this report, the trials are ordered in the sequence 
of the dates that the trial was opened (Table 1). 
Patient eligibility criteria 
The common eligibility criteria of the five trials in- 
cluded measurable breast cancer lesions where local ther- 
apy was indicated and surgery was not feasible. In addi- 
tion, treatment with a prescribed (re)irradiation schedule 
and HT according to the ESHO or Radiation Therapy On- 
cology Group (RTOG) guidelines (8, 12) were both fea- 
sible, and informed consent was obtained. In the MRC 
trials, patients were included if they were already on che- 
motherapeutic or hormone treatment, provided that their 
cancers were progressing locally. In the DHG, ESHO, and 
PMH trials, those on systemic chemotherapy were not el- 
igible but patients already on hormonal treatment were, if 
their local disease had progressed and required local 
intervention. 
Trial specific details are: 
(a) DHG 
Patients with breast cancer recurrences in previously 
irradiated areas, patients with recurrences in nonirra- 
diated areas, for whom shortened fractionation sched- 
ules were considered appropriate in view of poor per- 
formance status or long traveling distances, and others 
with inoperable recurrences in previously nonirra- 
diated areas who were considered fit for a high dose 
fractionated radiation schedule. After the ESHO trial 
had been opened, patients with recurrences in previ- 
ously irradiated areas were entered into the ESHO 
trial. 
(b) MRC BrI 
Patients with primary advanced (T3 or T4) disease that 
was deemed inoperable (13). 
(c) MRC BrR 
Patients with recurrent disease, with or without pre- 
vious irradiation. 
(d) ESHO 
Patients with recurrent disease within a previously ir- 
radiated area. 
(e) PMH 
Patients with postmastectomy recurrences with or 
without previous irradiation. 
Thus, within the combined trials, three groups of pa- 
tients can be distinguished. These are patients with un- 
treated primary inoperable breast cancer, those with re- 
current tumors in sites that had no previous irradiation, 
and those with recurrences in previously irradiated areas. 
Disease assessment 
Lesions were measured at entry to the trials and were 
classified as single or multiple, depending on whether or 
not there was more than one discrete area of tumor within 
the intended treatment area. The area of a single tumor 
was calculated as the product of the maximum diameter 
of the lesion and its perpendicular diameter. The area of 
multiple disease was the product of the maximum length 
and width of the area of disease to be treated. The depth 
was defined as the maximum tumor depth in the treatment 
area. The majority of these and subsequent measurements 
were verified independently by personnel other than the 
clinical coordinators. 
The presence or history of metastatic disease at the time 
of randomization was also recorded, although PMH was 
the only trial to conduct comprehensive staging prior to 
entry. 
Randomization 
In all trials, randomization was conducted by telephone 
call to a central office. In the DHG trial, stratification was 
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by participating center, whether or not previous RT had 
been given, and the preferred RT schedule. The two MRC 
studies were randomized, 40% to radiation only and 60% 
to the combined treatment, to provide more information 
on thermal parameters, which will be reported elsewhere. 
In the other trials, 50% of patients were allocated to each 
treatment arm. In the ESHO trial, stratification was by 
participating center and the diameter of the lesions (I or 
> 3 cm). In the PMH trial, patients were stratified ac- 
cording to whether or not previous RT had been admin- 
istered, area of disease (I or > 25 cm’), and tumor depth 
(5 or > 1 cm). 
In the ESHO and DHG trials, multiple lesions of one 
patient could be separately randomized and evaluated. 
However, for the purposes of this report, only one lesion 
per patient, the first randomized, is included. 
Radiotherapy and hyperthemia schedules 
Radiation was applied using either high voltage photons 
or electrons through one or multiple ports. Within the 
DHG, MRC BrR, and PMH trial protocols, radical and 
palliative schedules of RT were defined. Radical treat- 
ments were used where tumors occurred in areas that had 
not received previous radiation therapy. Palliative treat- 
ment was used for recurrences in previously treated areas. 
Details of radiation doses used in each trial are given in 
Table 2; the doses administered were the same, regardless 
of the outcome of randomization. 
To compare the various RT treatments given by the 
different groups, “effective doses’ ’ have been computed 
for each of the treatments, based on the linear quadratic 
formula with a/P taken as 10 and the correction for re- 
population based on 0.5 Gy per day, for a fraction size of 
2 Gy. These values have been converted to equivalent RT 
doses as given in 30 fractions over 6 weeks. The relation- 
ship between these doses is not very sensitive to the choice 
of value for a//3. The topic has been thoroughly reviewed 
by Steel (30). 
Hyperthermia treatments were given in accordance with 
quality assurance guidelines drawn up under the auspices 
of ESHO (12) or, in the case of PMH, RTOG (8). For HT 
treatment to be administered, patients were positioned on 
a couch. Thermometry probes were inserted into catheters 
that had been introduced into the tumorous area under 
local anesthesia and, also, placed on the tumor surface and 
on normal skin. Hyperthermia was induced using various 
externally applied electromagnetic applicators, most of 
which operated at 434 MHz. Current sheet applicators 
were used at Hammersmith, and water-filled waveguides 
in Amsterdam, Rotterdam, and Latina, Italy. In addition, 
dielectrically loaded waveguide applicators were used in 
Utrecht (custom-built), Trento ‘, Warsaw ‘, Graz ‘, Cam- 
bridge ‘, and Saarbrucken’. Warsaw and PMH used com- 
mercial dielectrically loaded waveguide applicators ‘, op- 
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erating at 915 MHz. The only HT treatment given at 
Sheffield involved a custom-built mechanically scanned 
2450 MHz air-filled waveguide. Except for this single 
treatment using the air-filled waveguide applicator, all 
treatments involved the use of a temperature-controlled 
water bolus that was either contained in a flexible bag or 
was an integral part of the applicator. 
In the DHG, MRC, and ESHO trials, the aim of each 
HT treatment was to achieve a minimum temperature of 
43°C at all sensors located within the tumor and to main- 
tain this for a period of 60 min. The hyperthermal treat- 
ment was considered to commence either 10 min after the 
electromagnetic fields were applied or from the time at 
which all sensors within the tumor recorded at least 43°C 
(if this was less than 10 mm), and to finish 60 min later. 
In the DHG trial, the total treatment time was 60 min. In 
the PMH trial, the intention was to reach a minimum tem- 
perature of 42.5”C at monitored locations in the tumor 
within 15 min and to maintain this for 30 min. 
Three measures of the actual HT treatments delivered 
were calculated for the MRC and PMH trials, and the 
treatments conducted in Rotterdam for the ESHO and 
DHG trials. These were the lower 90th percentile of all 
intratumor temperatures recorded during a treatment (T,,), 
the 50th percentile of all intratumor temperatures recorded 
during a treatment (T&, and the maximum intratumor 
temperature recorded during a treatment (Tmax,,,). Tem- 
peratures were recorded every 20 s at all sensors during 
the duration of treatment. In contrast to the other trials, in 
which stationary multisensor temperature probes were 
used, the PMH trial employed a thermal mapping tech- 
nique with generally two intratumoral sensors scanning 5 
mm continuously, through target volume, plus six surface 
sensors. 
Endpoints 
Local response. Local response was assessed according 
to the WHO criteria of objective response in measurable 
disease (35). Complete response of the treated area re- 
quired confirmation by a second consecutive observation 
at least 4 weeks after the first. Following this confirmation, 
the date of the CR was defined as the date of the first 
observation without evidence of tumor within the treat- 
ment area. 
Patients who either received no treatment or who died 
before response could be evaluated were classified as 
treatment failures (no CR). Death without a previously 
confirmed CR counted as a failure. Patients who achieved 
local complete regression only after the addition of a 
(new) systemic therapy were also classified as failures. 
Progressive disease was defined as a 25% increase in 
the size of measured lesions, or the appearance of new 
lesions within the treated area. Local progression was also 
deemed to have occurred if additional local treatment had 
’ BSD Corporation 2Lund Science, Buchler 
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Table 2. Treatment schedules and effective radiation doses for (re)irradiation plus hypertherxnia in the 5 trials 
DHG MRC BrI, PMH 
MRC BrR MRC BrR 
(Palliative) (Radical) (Palliative) (Radical) ESHO (Palliative) (Radical) 
Radiotherapy 
total dose (Gy) 32 40.5-50 28.8 50 32 32 50 
fraction size (Gy) 4 2-3 3.6 2 4 1.8 2 
overall time (weeks) 4 3-5 2 5 4 3.5 5 
boost (Gy) - lo-20 in - 1.5 in 5 - loin5 
5-10 fractions fractions 
fractions 
Effective radiation dose* 
(GY) 44.8 60.5-69.3 47.2 66.3 44.8 39.8 60.0 
Hyperthermia 
technique (MHz) 434 434 434 434.2450 loo- 1000 915 915 
allowed depth (cm) 54 =z4 54 54 54 52.5 12.5 
maximum number of 
applicators used 
simultaneously l-5 l-5 l-4 l-4 l-5 1 1 
margin around 23 cm 23 cm 50% SAR’ at 50% SAR at 50% SAR at 70% SAR at 70% SAR at 
macroscopic 10 mm depth 10 mm depth 5 mm depth 10 mm depth’ 10 mm depth* 
tumour 
HT-HT interval (days) 23 23 I 7 23 14 21 
Number of treatments, 
including boost 4-8 4-8 3 6 4-8 2 2 
Duration per treatment 
(min) 60 60 (10) + 60 (10) + 60 (10) + 60 (15) + 30 (15) + 30 
Target temperature “C 43 43 43 43 43 42.5 42.5 
RT-HT interval (mm) 30-60 30-60 290 290 30-60 <30 <30 
* Relative to 60 Gy given in 30 fractions in 6 weeks. 
+ Specific absorption rate. 
$ Determined by thermographic image. 
been given, whether or not a CR had previously been 
obtained. 
Time to local failure and distant progression. For pa- 
tients not reaching a CR, the time to local failure was set 
at zero, even if the patient initially showed a partial re- 
sponse or stable disease. For patients with a CR, time to 
local failure was the time to local progression from the 
date of randomization. Patients dying in local CR, or in 
continuing local CR at last follow-up, were censored at 
the date of death or last follow-up. 
The time to development of distant metastatic disease 
was recorded. 
Survival. Overall survival was calculated from the date 
of randomization to death or was censored at the date last 
known to be alive. 
Side effects. Acute and late toxicities for both RT and 
HT treatments were documented. Tolerance and patient 
acceptability of the treatments were also recorded for the 
MRC trials by means of a self-reported questionnaire 
completed by the patients. A quality of life study was also 
conducted at PMH. 
Data management. A common data set was defined for 
the combined interim and final analyses, although this un- 
derwent some revision toward the end of the trials. These 
data were abstracted from the data files of the individual 
trials. All data were sent to Rotterdam, the statistical cen- 
ter for the ESHO and DHG trials, for merging and anal- 
ysis. Data management of the DHG and ESHO trials used 
dBase III plus. COMPACT was used for data management 
of the MRC trials (6). For the PMH trial, the SAS database 
package was used. For analysis of the data, the statistical 
package STATA (29) was used. In COMPACT, a module 
was developed to export data into STATA format. 
Interim analysis and data monitoring. After the deci- 
sion to combine the trials had been made, with a combined 
recruitment target of 280 patients, subsequent interim 
analyses were planned once a year, with emphasis on the 
monitoring of the trials, in particular, the accrual. A formal 
stopping rule based on the interim results of the combined 
data was not defined, because this could interfere with the 
design objectives of the individual trials. However, the 
following pragmatic guideline based on the intention to 
treat principle was adopted (17): 
‘ ‘At interim analyses tests of differences would be per- 
formed for each trial on an annual basis. The results would 
not be disclosed to participants unless both the ESHO trial 
and the MRC BrR trial showed a statistically significant 
difference (two-sided test) in the CR rate between treat- 
ments withp < 0.05 and the combined analysis of all trials 
would be statistically significant with p < 0.001.” 
On this basis, the decision to stop or continue each trial 
was left to the specific coordinating committee. 
Statistical analysis. Logistic regression stratified by 
trial was used for the evaluation of the differences between 
treatments in CR rate and for the calculation of ORs and 
associated 95% confidence intervals (CI), an OR < 1 in- 
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dicating a benefit of the addition of HT (2, page 269). The 
sizes of the boxes in Fig. 1 are proportional to the standard 
error of log OR, and give an indication of the relative 
precision of the estimate of the OR for each trial. Time to 
local failure and survival were analysed using Kaplan- 
Meier curves, the logrank test and the Cox proportional 
hazards model. For these analyses, the relative efficacy of 
the two treatments was assessed by the hazard ratio (HR) 
and the associated 95% CIs, a HR < 1 indicating a benefit 
from the addition of HT (22). 
RESULTS 
There were 3 17 lesions randomized in 307 patients. Of 
these, one patient was excluded because she had micro- 
scopic nonmeasurable disease and, therefore, had been 
randomized in error. She was treated with RT only, ac- 
cording to randomization, and maintained local control to 
the time of this analysis 5 years later. Ten secondary le- 
sions are not included in the analysis. Eight of these were 
from patients with multiple lesions that were separately 
randomized at entry to the trials, and two were MRC BrR 
patients who had previously been entered into MRC BrI. 
Of these 10 lesions, 7 were randomized to combined ther- 
apy, of which 3 achieved CR and, of these, none relapsed 
locally. Two patients were still alive after 3 years. Of the 
3 randomized to RT only, none achieved CR. 
The remainder of this report refers to the remaining 306 
lesions in 306 patients. 
Following interim analyses in 1991 and 1992, the third 
interim analysis, carried out in July 1993, fulfilled the cri- 
Trial 
No of CRslNo 
randomised 
RT RT+HT OR 95% Cl 
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teria for disclosure and, at the same time, recruitment had 
reached 269 patients, nearing the target number of 280. 
At a meeting of all the participants concerned, it was de- 
cided to continue accrual until the end of 1993, and then 
close the trials. 
The final analysis was conducted in June 1994, ensuring 
a minimum follow-up of 5 months for all patients. 
Patient characteristics 
The pretreatment characteristics including age, disease 
status, previous irradiation, systemic therapy prior to ran- 
domization, presence or history of distant metastases, lo- 
cation, size and extent of the lesions of the 306 patients 
recruited are summarized in Table 3. There are some clear 
differences between trials that reflect the different eligi- 
bility criteria within the respective protocols. For example, 
patients with chest wall and multiple lesions are included 
in all trials except MRC BrI, and nodal disease was treated 
in all except the MRC trials. 
In 152 patients (50%), there was no evidence or history 
of distant disease but, as already indicated, comprehensive 
staging prior to randomization was only carried out for the 
PMH patients. Two hundred and sixteen (71%) lesions 
were on the chest wall and 79 (26%) in breast tissue. One 
hundred and fifty-nine (52%) patients had single lesions. 
One patient in the MRC BrR trial was male and received 
RT only. 
In the combined treatment arm, there was a higher pro- 
portion of patients who had received chemotherapy prior 
to randomization and the median lesion size was greater. 
There appears to be no obvious explanation other than 
Odds Ratio 
I  
1 
1 DHG 14119 14119 1.0 0.2 1 - 4.2 ri 
I I 
1 
MRC Brl 8/l 2 1 O/l 8 0.6 0.1 - 2.9 
0 
I n 1 
I I I 
MRCBrR 17159 51190 3.2 1.6 - 6.5 , 
I 
I 
ALL 55/l 35 101/?71 2.3’ 1.4 - 3.8 +il+ 
I I I I I I 
l obtained after stratification by trial “4 14 1 2 4 a 16 
HT worse HT better 
Fig. 1. The OR for a CR by trial, with associated 95% confidence intervals. 
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chance for these imbalances, but they are adjusted for in 
the analysis presented below. 
Treutment received 
Ninety-five percent of patients received the treatment 
to which they were randomized. Details of the treatments 
administered are summarized in Tables 4 and 5. 
There were 11 patients (5 randomized to RT and 6 to 
RT + HT) who received no treatment because of disease 
progression. One patient allocated to RT only refused 
treatment and one allocated to RT only received combined 
treatment (five sessions of HT). The majority of patients 
received palliative doses of RT because they had been 
previously radically irradiated, although the ESHO trial 
was the only one in which all patients had been previously 
irradiated. 
Although the intention in all HT treatments was to raise 
intratumor temperatures to a minimum of 43°C (42.5”C in 
the case of PMH), this target was not achieved in the ma- 
jority of treatments. The results of an analysis of the actual 
temperatures achieved, in terms of three thermal param- 
eters previously shown to be reasonable descriptors of HT 
treatment (7), are given in Table 5. In general, the duration 
of treatments actually delivered was similar to that in- 
tended (see Table 2). 
Local response 
The number of patients and CRs by trial and treat- 
ment group are given in Table 6, together with the me- 
dian time to CR and details of disease progression and 
survival. 
Fifty-five of the 135 patients randomized to RT alone 
(4 1%) and 101 of the 17 1 of the patients randomized to 
Volume 35. Number 4. 1996 
RT + HT (59%) had a CR. This difference, following 
logistic regression analysis stratified by trial, is statisti- 
cally significant with p < 0.001, and translates into an 
OR Stratified = 2.3 (95% CI 1.4 to 3.8). However, as is shown 
in Table 6, there is considerable variation in the CR rates, 
and the corresponding ORs, observed in the five trials. As 
we have already indicated, the two largest studies (ESHO 
and MRC BrR) both show a statistically significant @ = 
0.004 and 0.001, respectively) advantage for the addition 
of HT, whereas the other three trials do not show a benefit 
(ORs < 1). Such variation in the ORs may be explained 
by the small patient numbers in these trials, because a 
formal test for interaction indicates that there is not a sta- 
tistically significant difference in HT effect among the 5 
trials @ = 0.14). Even though the individual trial results 
differ, they are not inconsistent with an advantage for HT, 
as is indicated by Fig. 1. 
Univariate analysis of the effect of baseline character- 
istics on the CR rate showed that it depended strongly on 
the size of the tumor (CR rate 70% for lesions with area 
< 16 cm2 compared to 45% for lesions with area z 16 
cm2), the depth of the lesion (CR rate 60% for lesions 
with a depth < 3 cm, vs. 38% for lesions with depth 2 3 
cm), and on a history or presence of metastatic disease 
outside the treatment area (CR rate 39% vs. 63%). This 
last effect is caused by the higher death rate of patients 
with a history of metastatic disease. These patients had a 
higher risk of dying from progression elsewhere, and the 
tumor in the treated area had not yet had the time to dis- 
appear completely. In the multiple logistic regression 
analysis, stratified by trial and adjusted for the baseline 
characteristics that were individually prognostic for CR 
(maximum diameter, area of lesions, and systemic dis- 
ease), the benefit of the addition of HT to RT was con- 
Table 4. Summary of radiotherapy treatment received in each trial 
Total 
Treatment deviations 
Allocated RT 
No treatment 
RT + HT 
Allocated RT + HT 
No treatment 
Radiotherapy, total dose (Gy) (actual) 
No RT 
<28 
28-32 
33-40 
41-50 
51-60 
61-70 
Dose in relation to previous RT:Mean 
(SD) 
primary 
recurrent no RT 
recurrent RT 
DHG 
38 
- 
- 
1 
1 
1 
11 
- 
1 
6 
18 
59 (15) 
31 (3) 
MRC BrI MRC BrR 
30 149 
- 4 
- 1 
1 3 
1 7 
1 9 
- 105 
2 14 
3 6 
9 6 
14 2 
58 (12) - 
- 47 (12) 
- 29 (2) 
ESHO 
56 
1 
- 
1 
2 
2 
52 
- 
- 
- 
- 
- 
3 lj3) 
PMH 
33 
- 
- 
- 
- 
1 
19 
- 
- 
13 
- 
58 (8) 
33 (8) 
Total 
306 
5 
1 
6 
11 
14 
187 
16 
10 
34 
34 
58 (12) 
55 (14) 
30 (4) 
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Table 5. Summary of hyperthermia treatment received in each trial 
DHG MRC BrI MRC BrR ESHO PMH Total 
Hyperthermia, (number of 
treatments) 
0 
1 
2 
3 
4 
5 
6 
8 
Thermal parameters, 
median (range) 
T90 ("Cl 
TAO ("'3 
Tmax,, (“C) 
Duration of each 
treatment (min), 
median (range) 
No of intra-tumor 
sensors, median 
(range) 
1 1 3 
- - 2 
- - 5 
1 1 73 
1 4 4 
9 1 3’ 
1 11 - 
6 - - 
1 - 6 
- - 2 
17 22 
1 - 76 
- - 9 
5 - 18 
1 - 13 
19 - 25 
t t 
39.0 (35.7-41.1) 40.4 (37.6-42.7) 40.7 (34.6-43.3) 39.5 (37.6-41.5) 40.7 (39.5-43.0) 
40.7 (39.3-42.2) 42.3 (39.2-44.4) 42.5 (40.2-44.7) 41.1 (38.5-42.9) 42.2 (41.0-43.6) 
43.5 (41.9-50.7) 45.1 (41.0-47.5) 45.6 (42.0-49.1) 43.3 (39.8-44.7) 44.6 (43.4-46.5) 
60 (55-61) 60 (30-60) 60 (17-65) 60 (60-60) 28 (22-36) 
7 (4-13) 10 (4-20) 10 (3-36) 6 (O-11) 28 (7-52)” 
* In addition, one patient allocated RT received RT plus 5 HT treatments. 
’ Thermal parameters for Rotterdam patients only. 
’ Thermal mapping. 
firmed and enhanced, ORAdjusted = 3.0, 95% CI 1.7 to 5.1 the lesions (80%) in areas without previous radiation re- 
0, = 0.0001). ceived radical treatment with doses over 40 Gy. 
Primary lesions, or recurrent lesions in an area not pre- Even though the differences in treatment effects be- 
viously irradiated, had a higher CR rate (61%) than re- tween the studies are not inconsistent with an overall ben- 
current lesions in a previously irradiated area (46%). Le- efit of HT, as measured by a combined OR, the differences 
sions in an area exposed to previous radiation received could be caused by clinically relevant differences in pa- 
palliative doses of radiation around 28 Gy, and most of tient characteristics and, associated with this, in radiation 
Table 6. Percentage of CR, median time to CR, disease progression, and survival, by trial and treatment 
DHG MRC BrI MRC BrR ESHO PMH TOTAL 
RT RT+HT RT RT+HT RT RT+HT RT RT+HT RT RT+HT RT RT+HT 
Total 19 19 12 18 59 90 29 27 16 17 135 171 
CR 14 14 8 10 17 51 11 21 5 5 55 101 
% 74 74 67 56 29 57 38 78 31 29 41 59 
Difference 0 -11 28 40 -2 18 
OR 1 .oo 0.65 3.23 5.73 0.92 2.30* 
Median time to CR 
(days) 105 77 399 149 84 77 90 70 127 91 101 81 
Local recurrence after 
CR 6 3 - 1 6 3 4 8 1 2 17 17 
Progression elsewhere 9 11 2 3 12 42 7 18 1 1 31 75 
Dead 2 6 2 4 9 36 3 6 - - 16 52 
No CR 5 5 4 8 42 39 18 8 11 12 80 70 
Progression elsewhere 5 3 4 5 33 31 14 5 10 11 66 55 
Dead 4 3 4 5 35 36 9 4 6 6 58 54 
All Patients, % 
Actuarial survival 
at 2 year (SE) 65 (12) 62 (13) 48 (15) 44 (12) 32 (6) 21 (5) 42 (11) 68 (10) 46 (17) 59 (13) 41 (5) 36 (4) 
* Estimated using logistic regression stratified by trial. 
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Fig. 2. Local failure-free curves by arm; pooled 
treatment characteristics between the studies. Therefore, 
interactions between the HT treatment effect and the 
above-mentioned prognostic factors were studied. No sig- 
nificant difference in treatment effect between small le- 
sions (< 16 cm’) and large lesions (Z 16 cm’) was found 
(JJ = 0.41). The HT effect was somewhat less with deeper 
tumors, but this was far from statistically significant @ = 
0.21). Also, the presence or a history of metastatic disease 
was not related to the HT effect (p = 0.70). There was, 
however, a clear interaction between palliative and radical 
RT in terms of HT effect (p < 0.01). In the group of 
patients with lesions in areas not previously irradiated, 
generally treated with radical RT, no difference in CR rate 
was found between those in the RT arm (n = 45, CR = 
60%) and those in the combined treatment arm (n = 5 1, 
CR = 63%), with an OR = 1.24 (95% CI 0.46, 3.32). In 
the group of patients with lesions in previously irradiated 
areas, treated with palliative RT doses, the CR rate in the 
combined treatment arm was much higher (n = 120, CR 
= 57%) than in the RT only arm (n = 90, CR = 31%). 
The corresponding OR in this subgroup is 4.7 (95% CI 
2.4-9.5). 
The median time to response was shorter by approxi- 
mately 3 weeks for patients subjected to the combined 
treatment, as opposed to RT alone, (Table 6), although the 
magnitude of this difference varied from trial to trial. 
Duration of response 
All patients who did not reach a CR were considered 
to be local failures. Of the patients who achieved a CR, 
17% of those receiving RT + HT, and 3 1% of the RT only 
patients had a local relapse during follow-up. Figure 
2 shows the actuarial local relapse-free survival for the 
two treatment arms pooled over the trials. Patients who 
did not reach a CR were considered failures on the day of 
randomization. After that day, failures are patients with 
local relapse. Patients who did not relapse were censored 
either at death or at the time of last follow-up, as appro- 
priate. These curves show that the advantage of HT is 
maintained during follow-up. A Cox regression analysis 
gave a HR, for RT + HT compared to RT alone, of 0.67 
(p = 0.007, 95% CI 0.5-0.89). 
Distant progression and survival 
About 50% of the patients already had a history of met- 
astatic disease or active disease outside the treatment area 
at the time of randomization (Table 3). The majority of 
the patients (227 of 306 or 74%) showed progression out- 
side the treatment area during follow-up (Table 6). This 
had a major impact on survival and explains why the 
higher local CR rate with HT is not reflected in a survival 
advantage. Only 4 of the CR patients died without evi- 
dence of progressive disease elsewhere. 2 of them in con- 
tinuous local CR and 2 after a local relapse. Of the CR 
patients, 64 died with distant progressive disease, 56 of 
them still in local CR. Of the patients who did not reach 
a CR, 112 have died, almost all of them (91%) with pro- 
gressive disease outside the treatment area. 
The survival experience is summarised in Fig. 3 and 
Table 6, indicating a median survival of approximately 18 
months irrespective of treatment received. The 2-year ac- 
tuarial survival rate for all patients was approximately 
40%. Between-trial differences reflect the respective pro- 
tocol eligibility requirements, as well as differing disease 
status at entry; for example, the MRC BrR trial contains 
a high proportion of patients with metastatic disease or a 
history of metastatic disease at randomization. 
Side effects and toxicity 
Overall, both treatments were well-tolerated, with no 
patients refusing to complete the prescribed radiation, but 
a small number of patients had their HT treatments ter- 
minated early because of pain. In addition, two patients 
had HT halted because of the discovery of pleural effu- 
sions that made it impossible for them to lie flat. 
Because of the different scales used, a detailed com- 
parative analysis of the degrees of toxicity experienced 
across all trials is not possible, but the common acute and 
d I lb 
I 
2b 
I 
3i 
Survival [months1 
Fig. 3. Overall survival by arm; pooled 
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late side effects of therapy are summarized in Table 7 by 
treatments received, for those patients for whom this in- 
formation is available. 
In terms of acute reactions, there is little difference in 
erythema and desquamation between treatments but, as 
expected, more blistering occurred with the addition of 
HT (11%) as compared to RT alone (2%). This excess is 
noted in all trials except MRC BrI, where no blistering 
occurred in either treatment arm. Similarly, acute effects 
of HT were 7% ulceration and 7% necrosis in the com- 
bined arm, compared with 2% and l%, respectively in the 
RT-only arm. These were greatest in the MRC BrR trial, 
where 10% of patients receiving HT suffered some early 
necrosis. In general, the acute effects of HT treatment 
tended to occur in areas of reduced sensitivity and healed 
with conservative treatment, with little impact on patient 
well-being. 
Severe late reactions occurred: 1 each of bone necrosis, 
bone fracture, and brachial plexus lesion, all in the com- 
bined arm of the ESHO trial. The late effects of pigmen- 
tation, telangiectasia, and fibrosis show very little varia- 
tion between treatments. 
Thus, HT, as delivered in these trials, was well tol- 
erated and did not significantly add to either the clini- 
cally relevant acute or long-term toxicity over irradia- 
tion alone, even in those patients who had received prior 
radical RT. 
DISCUSSION 
The trials presented in this paper result from a mul- 
ticenter international collaboration, and the analysis has 
demonstrated a statistically significant benefit from the 
use of HT, in addition to radiation, in superficial breast 
cancer. 
In view of the need for quality assurance for HT treat- 
ment highlighted in previous trials (23), an effort was 
made to ensure that only tumors that could be heated sat- 
isfactorily would be entered into the trials. For this reason, 
quality assurance guidelines based on general experience 
Table 7. Summary of recorded treatment-related toxicity by trial and treatment 
DHG MRC BrI MRC BrR ESHO PMH TOTAL 
RT RT + HT RT RT + HT RT RT + HT RT RT + HT RT RT + HT RT RT + HT 
Erythema (mild/mod) 
No II 
Yes 2 
Erythema 
(severeldesquamation) 
No 5 
Yes 8 
Blister 
No 13 
Yes 0 
Ulceration 
No 13 
Yes 0 
Necrosis 
No 13 
Yes 0 
Fibrosis 
No 6* 
Yes 4 
Telangiectasia 
No 8* 
Yes 2 
Pigmentation 
No 4* 
Yes 6 
9 7 11 21 46 11 10 7 5 
7 5 6 33 42 16 15 9 12 
8 12 15 48 77 18 17 10 9 
8 0 2 6 11 9 8 6 8 
15 12 17 53 82 27 20 15 13 
3 0 0 1 6 0 6 1 4 
16 12 16 52 85 27 22 16 16 
2 0 1 2 3 0 4 0 1 
17 12 16 53 78 27 26 16 
1 0 1 1 10 0 0 0 
5” 
4 
4 
8 
7 
10 
10 
7 
14 
3 
24* 24* 3’ 
14 35 4 
9* 8 
0 4 
27* 
11 
6* 
1 
3* 9 
6 3 
22* 
16 
39* 
20 
29* 
30 
1* 
6 
9* 
3 
10* 
2 
4* 
8 
9 
7 
- 
- 
11 
5 
17 
0 
10 
7 
- 
- 
12 
5 
57 81 
65 82 
53% 50% 
93 126 
29 37 
24% 23% 
120 
2 
2% 
147 
19 
11% 
119 
3 
2% 
155 
11 
7% 
121 
1 
1% 
154 
12 
7% 
46 55 
37 59 
45% 52% 
49 68 
18 29 
27% 30% 
47 62 
36 52 
43% 46% 
* Confined to patients with at least 1 year of follow-up. 
- Not recorded. 
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and consensus within the HT communities in Europe and 
North America (8, 12) were adopted. In addition, quality 
assurance programs in some institutes were assessed dur- 
ing site visits carried out under the auspices of ESHO (16). 
Superficial breast cancer was chosen for the trials be- 
cause, even within the limitations of available HT equip- 
ment, it was felt by the individual trial groups that it was 
feasible to heat the relatively shallow lesions adequately 
and to obtain satisfactory measurements of the tempera- 
ture distribution at several locations within the treated 
field. 
The combined therapy was well tolerated and did not 
result in major toxicity. There were, however, differences 
in outcome between the individual trials with two, MRC 
BrR and ESHO, illustrating an advantage for HT. In the 
DHG trial, there was no apparent difference between the 
treatments and MRC BrI and PMH indicated a small ad- 
vantage for RT alone. Note, however, that all of the 95% 
CIs for the odds ratios (OR) from the five trials are not 
inconsistent with a substantial benefit from HT (Fig. 1). 
Overall survival did not differ markedly between the 
two treatment arms, although the pooled data suggest that 
the group receiving additional HT has a marginally infe- 
rior survival, as shown in Fig. 2. This may be caused by 
lesion size, which has been shown to be of prognostic 
value for overall survival (4), and was larger in the com- 
bined treatment arm. 
We have shown that size and depth of lesions, distant 
metastatic disease, and RT dose are important factors that 
affect CR rate. The patients in these trials are heteroge- 
neous in these respects and this accounts, in part, for the 
variable CR rates between the trials. However, following 
adjustment for these factors, there remains a statistically 
significant difference in CR rate in favor of HT. The num- 
bers of patients in the individual trials are small and any 
inferences drawn from the inter-trial differences may, as 
a consequence, be unreliable. Nevertheless, these differ- 
ences do raise some interesting questions with regard to 
the possible differences in efficacy of varying RT and HT 
regimens. which are testable hypotheses for future trials. 
There are differences within the five trials that may be 
important. All the MRC BrI patients, approximately two 
thirds of the DHG patients, and a smaller proportion in 
the MRC BrR and PMH trials, received radical RT. The 
MRC BrI patients had primary breast cancer that was 
deemed inoperable because of disease extent, and these 
lesions were probably more difficult to heat adequately. 
The depths of these tumors were estimated clinically and 
it is possible that this may have been underestimated. 
These patients, therefore, may not have complied with the 
guidelines for HT. The lesion sizes of the DHG patients 
were smaller. and we would expect all such patients to 
achieve a higher CR rate. The treatments delivered also 
varied between trials. Estimates of the equivalent radiation 
doses showed considerable differences between the pal- 
liative schedules, although the radical doses were less 
variable. Bedwinek et al. (3) have defined ‘adequate’ RT 
doses for recurrent tumors of different sizes and depths. 
However. tumors in previously irradiated areas cannot be 
adequately treated by RT alone because of the effect on 
normal tissues, and because the hypoxia induced by pre- 
vious RT renders the tumor less sensitive to the effects of 
radiation. We believe that it is important to give the max- 
imum tolerated dose of radiation, even in those patients 
who have received previous radiation. to achieve the high- 
est possible CR rates. There was significant variation in 
the prescription of heat treatments in the different trials. 
hence, making the establishment of a heat-response rela- 
tionship difficult. It would appear, however, that the PMH 
trial had the lowest number and duration of heat treat- 
ments, with the lowest CR rate achieved for the combined 
treatment arm. A number of possibilities may account for 
this outcome, such as the small number of patients, vari- 
ation in clinical characteristics, and low RT dose. but the 
possibility that this may have been influenced by the heat 
treatments cannot be excluded. 
The combined results reported here have, we suggest, 
confirmed the view that the role of HT in the treatment of 
breast cancer is as an adjunct to a palliative dose of RT in 
patients with tumor recurrence following a radical course 
of treatment. 
These trials do not establish the beneficial use of HT 
for patients who are able to receive a full dose of radiation, 
but the numbers of patients treated radically in these trials 
is small and the apparent lack of success with the addition 
of HT may be explicable by other factors, as already dis- 
cussed. Biologically, there is no reason why HT should 
not be of benefit in the radical situation, and future trials 
should look at these patients in greater numbers. 
The randomized trial reported by Overgaard et al. 
(21) in patients with recurrent or metastatic malignant 
melanoma treated by RT with or without HT, has shown 
CR rates of 46% for the combined arm and 28% for the 
radiation-only arm, which are similar to our own. This was 
a small trial based on only 71 patients with 134 lesions, 
and the form of analysis used leads to some doubt as to 
how reliable these estimates of CR really are (19). How- 
ever, both this trial and our own, with the CR rate at 2 
years of 59% for irradiation plus HT vs. 41% for irradi- 
ation alone, is in keeping with other Phase III randomized 
trials. Following the results of our trials, we could rec- 
ommend the consideration of HT for patients with recur- 
rent breast cancer to be retreated with irradiation. We hope 
that these results will encourage the use of HT in clinical 
practice and, also, further study into its use in other tumor 
types, as well as the best scheduling of HT and radiation. 
Further research is also required to assess the benefit of 
HT on those patients for whom radical radiation is 
planned. 
We would emphasize that, without the international col- 
laboration, each of these five trials would have been too 
small to contribute meaningful data on the role of HT in 
superficial breast cancer. This must have important impli- 
cations for the planning of future trials. 
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